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Abstract
There is considerable controversy regarding the possible over-treatment of patients with mild Cervical 
Intraepithelial Neoplasia (CIN), with lesions being often excised or ablated. Thus, identifying the markers of 
potentially malignant lesions would be of a great prognostic value. In the current study, we hypothesized that using 
colposcopic, cytological and histological findings together with assessing the expression of molecular growth factors 
can predict CIN outcome. The study group consisted of 285 women between 19 and 81 years of age (median age, 
37,8 years). The follow up were 60 months and considered 138 women: 50 women with Subclinical Papillomavirus 
Infection (SPI), 50 women with CIN1 and 38 women with CIN2.
All patients underwent cytology, colposcopy, and sampling for subsequent testing for HPV. In cases in which 
colposcopy suggested the presence of suspicious lesions, biopsy specimens were taken. HPV DNA was genotyped 
for HPV types 16, 18, 31, 33, and 45 by multiplex PCR. Transcripts of HR HPV types 16, 18, 31, 33, and 45 were 
detected by the NucliSens EasyQ HPV assay. The VEGF expression was analyzed with immunohistochemistry, 
RNA extraction, cDNA synthesis and RT-PCR analysis and Western blot. 
We found that so called lymphangiogenetic switch (over expression of VEGF C and VEGFR-2) appears already 
in CIN 2, which is a rare observation, Persistent HPV HR infection is not only a trigger but also a maintenance factor 
in the cervical carcinogenesis. CIN2/3 and cervical cancer is in high percentage associated with the presence of HR 
DNA HPV as well as E6/E7 DNA mRNA.
In CIN2/3 and cervical cancer VEGF and its receptor expression correlate with the stage of cervical carcinogenesis.
Progression of cervical intraepithelial neoplasia occurs when co expression of all: HR DNA HPV, E6/E7 HR HPV 
mRNA and VEGF is present.
Keywords: CIN (Cervical intraepithelial neoplasia); Cervical cancer;
VEGF; VEGFR; DNA HPV; mRNA E6/E7 HPV
Introduction
Cervical cancer is the second most common cancer in women 
and the leading cause of cancer-related death in females from 
underdeveloped countries. Each year, approximately 500,000 cases of 
cervical cancer are diagnosed worldwide. 
Routine screening has decreased the incidence of invasive cervical 
cancer in the United States, where approximately 13,000 cases of 
invasive cervical cancer and 50,000 cases of cervical carcinoma in situ 
(i. e. true precancer) are diagnosed annually [1]. 
Cervical cancer arises from the metaplastic epithelium of the 
Transformation Zone (TZ) (squamocolumnar junction) and develops 
slowly through progressive dysplastic changes to Carcinoma In Situ 
(CIS) and invasive cancer. Cervical Intraepithelial Neoplasia (CIN) is 
divided into three stages according to the degree of epithelial dysplasia 
and differentiation. Lesions are accessible to colposcopic evaluation 
and biopsy, which makes monitoring disease progression relatively 
easy. Low grade lesions (i.e. CIN1) and, in some cases CIN2 may 
spontaneously regress or not progress further, while the malignant 
potential of CIN 3 is 36% over 20 years [2]. 
There is considerable controversy regarding the possible over-
treatment of patients with mild cervical abnormalities, with lesions 
being often excised or ablated. Thus identifying the markers of 
potentially malignant lesions would be of great prognostic value [3]. 
The most common types of Human Papillomavirus (HPV) found 
in CIN and cancer patients are types 16, 18, 31, 33, and 45 [4]. Persistent 
infection with these types is regarded as the earliest carcinogenesis 
stage [5]. The role of HPVs in the etiology of cervical cancer is tightly 
correlated with the overexpression of two oncogenes (E6 and E7) due 
to a specific opening in the E2 open reading frame in the integrated 
viral genome [6]. Studies of cervical cancer cell lines and cancer biopsy 
specimens have shown that the continuous expression of these genes 
is a necessary condition for the transformation and maintenance of 
neoplastic and dysplastic cells [7-10]. 
In recent years, many studies have shown that testing for HPV DNA 
can improve the detection of High-Grade Squamous Intraepithelial 
Lesions (HSILs) and cervical cancer [8-12]. This suggests that DNA 
testing can make a useful contribution to the triage of women with 
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an equivocal cytology finding and for follow-up after the treatment 
of precursor lesions. However, the high prevalence of transient 
and asymptomatic HPV infections means that DNA tests have low 
specificities. Identification of the persistent infections likely to produce 
high-grade lesions currently requires repeated monitoring of the HPV 
DNA types. Commercial nucleic acid sequence-based amplification in 
a real-time format allows the reliable type-specific detection of E6 and 
E7 mRNA from HPV types 16, 18, 31, 33, and 45. Several authors have 
thus suggested that RNA-based assays could be more effective than 
DNA testing in risk assessment [13-18]. 
The development of cervical cancer as well as other malignant 
tumors has conventionally been considered to follow a pre-vascular 
phase, where the growth of the primary tumor is restricted to a few 
millimeters in diameter due to the diffusion limit of oxygen [19]. 
Vascular Endothelial Growth Factor (VEGF) is one of the most specific 
and strongest growth factors for the endothelial cells among all the 
factors that have been discovered so far. VEGF, a multifunctional 
cytokine, stimulates angiogenic activity by increasing vascular 
permeability and acting as an endothelial cell mitogen. The protein 
family includes the following: VEGF- A [14], -B [15], -C [16], -D [17], 
-E [18] and placenta growth factor (PIGF) [20]. 
In this study, we evaluated the correlation between VEGF-C and 
VEGFR-2 and clinicopathologic parameters in cervical cancer. 
In the current study, we hypothesized that using colposcopic, 
cytological and histological findings together with assessing the 
expression of molecular growth factors can predict CIN outcome. 
Materials and Methods
Cervical specimens were collected from October 2006 to December 
2007 from patients admitted for secondary screening to the Colposcopy 
Outpatient Service and the Gynecological Oncology Unit (Jagiellonian 
University Medical College, Krakow, Poland). The study group 
consisted of 285 women between 19 and 81 years of age (median age, 
37,8 years).
In Poland the natonal screening for cervical cacner is an organized 
call- recall system with conventional Pap test as a screening tool. 
The triage for positive subject is colposcopy. The target population is 
women starting from 25 years of life, with 3 years interval. There are 16 
regional centers serving as the colposcopy clinics, where colposcopy is 
performed. After colposcopy the subject is reffered to treatment or is 
referred back to her primary physician. The database of the screening 
program is centralized and linked to the national healthcare system. 
The follow up period was 60 months and considered only 138 
women of whom the informed consent was obtain for this type of 
observation. The distribution of the observed women was: 50 women 
with SPI, 50 women with CIN1 and 38 women with CIN2. The Ethics 
Committee of Jagiellonian University Medical College approved the 
study protocol recommending surgery instead of follow-up of women 
diagnosed with CIN3. Written informed consent was obtained from all 
participants. All participants received a self-administered questionnaire 
requesting personal data, a gynecologic history, and information on 
exposure to risk factors. Women undergoing previously treatment 
for invasive cervical cancer were excluded. All patients underwent 
cytology, colposcopy, and sampling for subsequent testing for HPV. In 
cases in which colposcopy suggested the presence of suspicious lesions, 
biopsy specimens were taken. 
Follow up visits comprised of gynecological evaluation, Pap test, 
HPV sampling and colposcopy with cervical biopsy for histologic 
evaluation. The interval of visits was 6 months. The call-recall system 
was used. The SPI (sublinical papilloma infection) is a colposcopic 
term describing productive HPV infection, in which cytology presents 
koilocytosis or ASCUS results, and histology reveals no CIN but 
koilocytosis-presence of koilocytic epithelial cells with perinuclear 
halo containing HPV particles. The complete remission was defined 
as return to normal epithelium (no disease). The partial remission was 
defined as a step back in the sequence: normal, SPI, CIN1, CIN2 cervical 
tissue. The stationary state was defined as a persistency of SPI, CIN1 
or CIN2 diagnosis during observation. The progression was defined 
as any step forward in the sequence: normal, SPI, CIN1, CIN2, CIN3, 
cervical cancer. All diagnosis i.e. SPI, CIN1 and CIN2 were based on 
histologic evaluation. Cytology was based on a conventional Pap smear. 
The cytological diagnosis was made by specialized cytopathologists 
using the Bethesda classification system. Colposcopy was performed 
by specialized gynecologists. The results were reported following 
guidelines issued by PSCCP (The Polish Society of Colposcopy and 
Cervical Pathophysiology), a member of EFC (European Federation 
of Colposcopy) and IFCPC (International Federation of Cervical 
Pathology and Colposcopy). Histology was performed with specimens 
collected by colposcopy-directed biopsy (traditional punch biopsy 
specimens) and/or cone specimens collected by the loop excision 
procedure. Histology results were obtained for all 138 patients. 
Part of each tissue specimen was collected during surgery, one 
part for mRNA analysis - immediately frozen in RNAse later solution 
(Qiagen, Hilden, Germany), second part for protein analysis, both 
stored at -80°C until used for study. Cancer tissue preparation was 
done as reported by Molden et al. [21]. 
Cervical specimens for nucleic acid analyses were collected with 
a cervical brush by standard procedures. The material was preserved 
in PreservCyt/ThinPrep solution. Analyses were performed by the 
Virology Laboratory at the University Hospital, Krakow, Poland. 
HPV DNA was genotyped for HPV types 16, 18, 31, 33, and 45 by 
multiplex PCR. 
Samples were analyzed for HPV E6 and E7 mRNA by real-time 
multiplex nucleic acid sequence-based amplification. Transcripts 
of HR HPV types 16, 18, 31, 33, and 45 were detected by the 
NucliSens EasyQ HPV assay (bioMerieux, Poland), according to the 
manufacturer’s instructions. The VEGF expression was analyzed with 
immunohistochemistry, RNA extraction, cDNA synthesis and RT-
PCR analysis and Western blot analysis. 
Using the Shapiro–Wilk test, the distributions of countinous 
variables in the examined groups of women were analyzed and the 
results were presented as median values (minimum–maximum). U 
Mann-Whtney test or Kruskal–Wallis analysis of variance, with post 
hoc test (when appropriate) were used as distribution of analyzed 
variables differed from the normal ones or were quantitive data were 
analyzed. A p value of 0.05 was accepted as statistically significant. All 
calculations were carried out with the use of STATISTICA software 
v.9.0. (StatSoft, USA 2009) 
Result
Subclinical papilloma infection (SPI) and CIN outcome
(Table 1) 4–5-years clinical follow-up (cytologic-colposcopic) did 
not reveal statistically important differences in remission percentage 
of SPI women in comparison to CIN1 women. While remission was 
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statistically more often observed (p=0,038) in both SPI and CIN1 cases 
comparing to CIN2. 
The stationary status was statistically more frequently observed 
(p=0,050) in women with CIN1 comparing to SPI women. Analogically, 
in cases of CIN2 the stationary status was observed more often (p=0,022) 
comparing to SPI women. There were no statistically important 
differences between stationary status of women with CIN1 and CIN2. 
This may be the proof of non-stable, dynamic SPI characteristic, 
influenced by immunological factors. Such a concept may be also 
confirmed by higher SPI remission percentage in comparison toCIN1 
andCIN2. Number of SPI, CIN1 and CIN2 was calculated in complete 
remission group and compared with the progression group (Yeats ch2 
(7,46) ; p=0,024). There were no statisticall difference between CIN 1 
and CIN 2, between SPI and CIN, but there was statistically important 
difference between SPI and CIN 2 ( p=0,006).
SPI, CIN 1 and CIN2 outcome and HPV DNA type
During prospective, clinical observation, the highest remission 
percentage was noted in SPI (76,0%) women and the lowest one in CIN2 
(36,8%) group of women. In these lesion, the low risk (LR) DNA HPV 
was noted in 78,2% cases, high risk (HR) and LR DNA HPV–in12,8% 
cases, and in 9% of women no DNA HPV was detected using HC2 test. 
While, the progression rate was the lowest in SPI (12,0%) women, and 
the highest in CIN2 (31,6%) cases, the progression in 96,3% of cases 
was accompanied with HR HPV DNA and only in one case (3,7%) with 
LR HPV DNA. These observations confirmed the importance of HR 
HPV DNA in cervical carcinogenesis. In the Table 1 the remainder was 
the cases of stationary state. 
SPI, CIN 1 and CIN2 outcome and E6/E7 mRNA HPV 
expression
The analysis on SPI, CIN 1 andCIN 2 outcome in relation to E6/
E7 HPV 16, 18, 31, 33 and45 mRNA expression revealed that in 138 
women who were observed presented that progression occurred overall 
in 20/22 (90.9%) mRNA (+) and 7/83 (8.4%) mRNA [-]. The remission 
rate was be 91.6% for mRNA [-] and 9.1% for mRNA [+] (Table 2). 
The progression/remission analysis revealed that CIN 1 and CIN 
2 remission in 55/60 (91,6%) occurs when there are not E6 and E7 
HPV mRNA expression. The progression occurred in 9/11 (91.6%) of 
cases of SPI andCIN1 and 11/11 (100%) of cases of CIN 2, in which the 
E6/E7 HPV mRNA was detected. Persistent HR HPV infection is an 
important factor in cervical carcinogenesis. 
SPI, CIN 1 and CIN2 outcome and VEGF expression
Assuming this is the Mann-Whitney U test, there was a significant 
difference in the VEGF expression between the groups of women 
who regressed compared with those who progressed. The median 
VEGF expression in group of SPI, CIN 1 and CIN 2 women which 
spontaneously regressed was 18,98 pg/ml. This expression was 
statistically lower than median VEGF expression of SPI, CIN 1 and 
CIN 2 women, which progressed. In these cases the median VEGF 
expression was 34,72 pg/ml. The lowest value of VEGF expression 
(29,45 pg/ml) was reported it CIN2 cases which progressed to CIN3 
and CIS (Table 3). 
Normal cervical epithelium did not express VEGF-C or VEGFR-2 
in the samples analyzed. Significant differences were found between 
CIN1-2 and CIN3, but not between CIN3 and cervical cancer. 
VEGFR-2 expression was the strongest in the CIN3 samples, while in 
the group of CIN1, it was comparable to the control group. 
Discussion
In this paper in the women with histologically diagnosed Subclinical 
Papillomavirus Infection (SPI), CIN1, CIN2, CIN3 and cervical cancer 
the epidemiological, morphological and molecular factors impacting 
cervical carcinogenesis were evaluated. In the subgroup of 138 women 
with SPI, CIN1 and CIN2 prospectively observed for 4-5 years, the 
importance of DNA HPV, E6/E7 HPV mRNA expression and VEGF 
expression as potential predictive factors were measured. 
Despite of the fact, that the triggering factors in cervical 
carcinogenesis are pretty well studied [21] there are still gaps in the 
understanding of the mechanism, in which the CIN spontaneously 
regress, persists or progress into invasive cancer. 
This is of special importance, because CIN in most cases affects 
women in their procreative life time. Own experience [22] and many 
other authors observations [23-28], revealed that SPI in nearly 80%, 
CIN1 in 40–60%, and CIN2 in 30–35% of cases spontaneously regress. 
So in these cases therapeutic approach is unnecessary. Similar findings 
reported Cox and Schifman in ALTS study [29]. S240. In their study 
the DNA HPV, especially HR was related to higher percentage of SPI, 
CIN 1 and CIN2 progression to HSIL (CIN3+) (10%, 12,5% and 30,2% 
respectively). Similar findings reported Goldie et al. [30], Castle et al. 
[31], Insinga et al. [32] and Moore et al. [33]. 
According to many clinicians and molecular biologists E6/
E7 mRNA HPV expression is the sign of persistent HPV infection 
[21,27,28]. Moscicki et al. [34] and Castle et al. [31] state, that HPV-16 
persistency increases the risk of CIN3 development of 40% within 5 
years. Both transcriptors E6 andE7 HPV HR are stimulating cell cycle. 
They inactivate p53 andpRB, and stimulate replication and activate 
telomerase. 
Lesion N
Complete remission Progression
n % n %
SPI* 50 38 76,0 6 12,0
CIN 1 50 26 52,0 9 18,0
CIN 2* 38 14 36,8 12 31,6
Σ 138 78 56,5 27 19,6
*statistical significance at p=0,006
Table 1: Comparison of SPI, CIN 1 and CIN 2 complete remission and progression.
Lesion n
Remission Progression
mRNA (+) mRNA (–) mRNA (+) mRNA (–)
n % n % Σ n % n % Σ
SPI 50 1 2,6 37 97,4 38 4 66,7 2 33,3 6
CIN 1 50 1 3,8 25 96,2 26 5 55,6 4 44,4 9
CIN 2 38 0 0,0 14 100,0 14 11 91,7 1 8,3 12
Σ 138 2 2,6 76 97,4 78 20 74,1 7 25,9 27
Table 2: SPI, CIN 1 and CIN 2 remission and progression and E6/E7 HPV 16, 18, 
31, 33 and 45 mRNA expression.
Lesion n
remission progression
VEGF (pg/ml) expression VEGF (pg/ml) expression
Min Max Me Min Max Me
SPI 50 16,00 18,24 16,76*;# 17,11 29,99 28,42*;##
CIN 1 50 17,12 19,11 17,98** 21,89 31,21 29,12**
CIN 2 38 20,99 22,45 21,13***;# 29,45 72,00 36,12***;##
Σ 138 16,00 22,45 18,98$ 17,11 72,00 34,72$
p <0,001*p<0,001;**p<0,001; ***p<0,001; $p<001; #p0=,008; ##p=0,039
Table 3: VEGF (pg/ml) expression and SPI, CIN 1 and CIN 2 outcome.
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The important issue in carcinogenesis studies is examining the 
neoangiogenesis. We found that so called lymphangiogenetic switch 
(over expression of VEGF C andVEGFR-2) appears already in CIN2, 
which is an original observation. In fact Van Trappen et al. [35] fund 
in 78% CIN3 lesions moderate to strong expression of VEGF-C and 
VEGF-D, but in CIN1 and CIN2 only in single cases. In our study we 
stated that VEGF expression May be useful as a progression indicator 
in CIN2 to CIN3. This is one of the first reports of such an observation 
confirmed in prospective observations. 
These observations confirm that VEGF is an important angiogenic 
factor in progression of cervical carcinoma and suggest molecular 
growth stimulation via VEGFR-2 in cervical carcinogenesis. Our 
results show that the switch to the lymphangiogenic phenotype occurs 
prior to the stage of invasion and probably between CIN2 and CIN3, 
and blocking VEGFR-2 signaling may represent a novel therapeutic 
approach to the treatment of a subset of cervix cancer and cervical 
intraepithelial neoplasia. 
Conclusions
Persistent HPV HR infection is not only a trigger but also a 
maintenance factor in the cervical carcinogenesis. 
In high percentage of CIN2/3 and cervical cancer cases HR DNA 
HPV and E6/E7 DNA mRNA are expressed. 
In CIN2/3 and cervical cancer VEGF and its receptor expression 
correlate with the stage of cervical carcinogenesis. 
Progression of cervical intraepithelial neoplasia occurs when co 
expression of at least one of factor: HR DNA HPV, E6/E7 HR HPV 
mRNA or VEGF is present. It seems that the more than one of these 
factors are expressed the trend of progression is stronger. 
We are aware that there are many reasons, some related to the 
process of screening why alternative explanation for the findings, 
including bias other than those we postulate could explain the findings. 
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